Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biomark DiagnosticsSTU:20B 27 EV-to-FCF is -53.73 as of Aug. 01, 2026. GuruFocus rates STU:20B with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 100 Medical Diagnostics & Research companies, Biomark Diagnostics ranks worse than 999999% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biomark Diagnostics's Enterprise Value is €36.27 Mil.
Biomark Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.68 Mil. Therefore, Biomark Diagnostics's EV-to-FCF for today is -53.73.
The historical rank and industry rank for Biomark Diagnostics's EV-to-FCF or its related term are showing as below:
STU:20B'
s EV-to-FCF Range Over the Past 10 Years
Min: -77.53 Med: -28.12 Max: 83.22
Current: -53.53
During the past 13 years, the highest EV-to-FCF of Biomark Diagnostics was 83.22. The lowest was -77.53. And the median was -28.12.
STU:20B's EV-to-FCF is ranked worse than 100% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.53
vs STU:20B: -53.53
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biomark Diagnostics's PE Ratio (TTM) for today is calculated as:
Biomark Diagnostics's share price for today is €0.318.
Biomark Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biomark Diagnostics EV-to-FCF Related Terms
Biomark Diagnostics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Biomark Diagnostics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biomark Diagnostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomark Diagnostics EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biomark Diagnostics's EV-to-FCF falls into.
Biomark Diagnostics's current Enterprise Value is €36.27 Mil.
Biomark Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomark Diagnostics (STU:20B) has a EV-to-FCF of -53.73 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biomark Diagnostics and its competitors. According to the industry distribution chart, Biomark Diagnostics ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry.
Is Biomark Diagnostics' EV-to-FCF too high?
Biomark Diagnostics' current EV-to-FCF is -53.73. Based on the distribution chart, Biomark Diagnostics ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biomark Diagnostics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomark Diagnostics ranks #999999 out of 100 companies for EV-to-FCF. This places Biomark Diagnostics in the lower half of its industry. The industry median EV-to-FCF is 26.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.53, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biomark Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomark Diagnostics's current EV-to-FCF is -53.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (STU:20B) has a current EV-to-FCF of -53.73. The current EV-to-FCF is -53.73. Biomark Diagnostics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biomark Diagnostics (STU:20B), the current EV-to-FCF is -53.73 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
27GF Score
Get the complete analysis for STU:20B
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:20B has been successfully added to your 
